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Aim: To evaluate the effect of propolis against Candida species planktonic cells and 
its counterpart’s biofilms. Materials & methods: The MIC values, time-kill curves and 
filamentation form inhibition were determined in Candida planktonic cells. The effect of 
propolis on Candida biofilms was assessed through quantification of CFUs. Results: MIC 
values, ranging from 220 to 880 μg/ml, demonstrated higher efficiency on C. albicans and 
C. parapsilosis than on C. tropicalis cells. In addition, propolis was able to prevent Candida 
species biofilm’s formation and eradicate their mature biofilms, coupled with a significant 
reduction on C. tropicalis and C. albicans filamentation. Conclusion: Propolis is an inhibitor of 
Candida virulence factors and represents an innovative alternative to fight candidiasis.
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Candida species are human commensal microbes that commonly reside on skin, GI tract, genitouri-
nary system, oropharynx and upper respiratory tract without causing harm to healthy individuals [1]. 
However, when the host immune and defense system are debilitated or under certain favorable condi-
tions, these species, which are opportunistic, can cause infections [2]. These infections can range from 
superficial, such as vulvovaginal, esophageal or oropharyngeal candidiasis, to life-threatening invasive 
disorders, including candidemia, which is associated with high mortality among immunocompromised 
populations [1].
For many years, Candida albicans has been reported as the predominant species responsible for 
the majority (60–80%) of infections caused by the genus Candida [3]. However, other non-C. albi-
cans Candida (NCAC) species, such as Candida glabrata, Candida tropicalis and Candida parapsilosis, 
have been frequently isolated mainly due to the indiscriminate prescription of antifungal agents [4–6]. 
Moreover, the pathogenesis of candidiasis is common to all Candida species and is facilitated by a 
number of virulent factors, including the ability to adhere to medical devices or host cells, biofilm 
development and filamentous form transition [7]. From a clinical point of view, Candida biofilms are 
associated with treatment failure due to a high level of antifungal resistance [8,9]. This fact triggers serious 
clinical concerns, not only regarding the treatment of patient infection but also for public health [10–12].
The increasing incidence of drug-resistant pathogens, limited number of therapeutic options 
and the toxicity of compounds have drawn attention towards the antimicrobial activity of 
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natural products encouraging the development 
of alternative treatments [13–15].
Propolis is a resinous substance that honey-
bees, especially Apis mellifera, collect from 
branches and flowers. It has a complex chemi-
cal composition and is known to be rich in 
poly phenols (mainly flavonoids), waxes, res-
ins, balsams, amino acids and other oils, thus 
propolis composition varies according to the 
plant source [16–18]. Propolis is reported to have 
a wide range of therapeutic properties, such as 
antimicrobial, antioxidant, anticancer, antivi-
ral, immunomodulatory, wound healing, and 
antiseptic effect [19–28].
Thus, knowing the problems associated with 
Candida infections, the development of alter-
native therapies, able to attenuate microbial 
virulence, is of utmost importance [29]. A little 
knowledge is already available regarding inhibi-
tion of virulence factors of C. albicans by propo-
lis [24,30–31]; nevertheless the knowledge concern-
ing NCAC species is still scarce. Therefore, the 
main goal of this study was to investigate the 
effect of propolis on clinical isolates of C. albi-
cans, C. parapsilosis and C. tropicalis planktonic 
cells and their counterpart’s biofilms.
Materials & methods
●● Origin of propolis, preparation 
& characterization of extract
Green Brazilian propolis was purchased from the 
company Mel Apinor (Wal-Luz apiary, Maringá, 
Paraná State, Brazil). This material was cooled at 
-18°C for at least 24 h. Then, in natura propolis 
was crushed in an industrial blender, packaged 
in plastic bags and stored in a freezer (-18°C).
The propolis extract (PE) was prepared from 
the previously reduced propolis, 30% (w/w) 
in ethanol by turbo-extraction technique [32]. 
Briefly, in a glass of turbo extractor, 30 g of prop-
olis were mixed with 70 g of ethanol (96%, v/v) 
and this system was kept in the refrigerator for 
24 h. After this period, the evaporated alcohol 
weight was completed and the mixture was sub-
jected to turbo extraction. Subsequently, it was 
vacuum filtered through filter paper and stored 
in amber glass bottle.
For the evaluation of the quality control of the 
PE, the techniques used were approved by offi-
cial codes and were described by many authors, 
namely relative density, pH, dryness residue 
(DR) and total phenol content (TPC) [18]. To 
determine the DR, an amount of 3.0 g of PE 
was evaporated in water bath, with slow shaking. 
Afterwards, the concentrated material was dried 
on the Ohaus-MB 200 infrared analytical bal-
ance (Pine Brook, NJ, USA), at 110°C until 
constant weight. The DR represents the average 
of, at least, three determinations. The TPC was 
measured by the Folin–Ciocalteau method with 
some modifications [33]. For that, in a 25-ml flask 
an aliquot of PE (2.0 μl) was mixed with 10 ml 
of purified water and 1 ml of phosphomolybdo-
tungstic reagent R (Folin–Ciocalteau). Then the 
volume was completed with an aqueous solution 
of sodium carbonate 14.06% (w/v). As compen-
satory solution, purified water was employed. 
The solutions were allowed to stand, protected 
from light for 15 min under room temperature 
and then the absorbance was read in a Shimadzu 
double beam UV-VIS spectrophotometer 
(Model 1650, Tokyo, Japan) at wavelength of 
760 nm. A calibration curve with different dilu-
tions of gallic acid was used as reference. Thus, 
the TPC was expressed as a percentage of total 
phenolic substances in PE. The tests accounted 
for an average of six evaluations.
●● Candida strains
Fourteen C. albicans (12 isolates from blood 
and two from urine), 14 C. parapsilosis (13 from 
blood and one from urine) and 14 C. tropica-
lis (four from blood and ten from urine), were 
used. Three Candida reference strains from the 
American Type Culture Collection (ATCC), 
namely C. albicans ATCC 90028, C. parapsilo-
sis ATCC 22019 and C. tropicalis ATCC 40042 
were included in this work. The clinical isolates 
from urine and blood were selected due to the 
high level of resistance to commercial antifun-
gals [34] and were obtained to archive collec-
tion of the Laboratory of Medical Mycology, 
Universidade Estadual de Maringá, Brazil.
In each experiment, the isolates were subcul-
tured on Sabouraud Dextrose Agar (SDA; Merck, 
Munich, Germany) or on Sabouraud Dextrose 
Broth (SDB; Merck, Munich, Germany) over-
night at 37°C. The cellular density was adjusted 
using a Neubauer chamber before each assay.
●● Effect of propolis on planktonic cells 
Antifungal susceptibility testing
The antifungal activity of PE was determined 
by the broth microdilution method accord-
ing to CLSI standard M27-A3 [35] with some 
modifications for natural products [36]. For 
this test, the serial dilution was performed 
at a ratio of two, from 1:2 to 1:1024. In this 
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way, PE’s concentrations ranged from 13.9 to 
7100 μg/ml of total phenol content expressed 
in gallic acid. The test was carried out in RPMI 
1640 (Roswell Park Memorial Institute, Gibco) 
with l-glutamine (with sodium bicarbonate) 
and 0.165 M 3-(N-morpholino)propanesulfonic 
acid (pH 7.2) as buffer (Sigma), and 2% glucose, 
in 96-well flat-bottomed microtitration plates 
(Orange Scientific, Braine-l’Alleud, Belgium). 
After incubation at 37°C for 72 h, MICs were 
determined by direct observation. The results 
of the MIC were considered relative to the TPC 
and were defined as the concentration of TPC 
that reduced 100% of the growth compared with 
the organisms grown in the absence of the drug. 
The minimum fungicidal concentration (MFC) 
was determined by seeding, on SDA plates, the 
suspensions exposed to different PE concen-
trations. Plates were then incubated at 37°C 
for 24 h. The MFC was defined as the lowest 
concentration of the test compound in which 
no recovery of microorganisms was observed. 
Fluconazole was used as a control (Pfizer, Brazil), 
and the tests were also determined according to 
the M27-A3 guidelines of the CLSI. The MIC of 
fluconazole was defined, as the lowest concentra-
tion of this antifungal that was able to inhibit 
50% of growth relative to the positive control 
without drug. As defined by the CLSI, nega-
tive controls (medium only), positive controls 
(medium and yeast), and the reference strain 
C. albicans ATCC 90028 were used in each test. 
The cutoff levels of susceptibility to fluconazole 
were used according to CLSI supplement M27-
S3 [37] to identify strains as susceptible (S), dose-
dependent susceptible (DDS) and resistant (R): 
fluconazole (S ≤ 8 μg/ml; DDS = 16–32 μg/ml; 
R ≥ 64 μg/ml).
Time-kill curve procedures
Time-kill curves were determined for the 
three Candida reference strains, C. albicans 
ATCC 90028, C. parapsilosis ATCC 22019 and 
C. tropicalis ATCC 40042 with slight modifica-
tions to that previously described [38]. Prior to 
testing, fungi were subcultured on SDA and the 
inoculum adjusted to 1- 5 × 105 yeasts/ml, in 
RPMI 1640 medium, using a Neubauer cham-
ber. Then, each Candida strain suspension was 
grown in the presence of PE at concentrations 
equivalent to 450 and 900 μg/ml of TPC. The 
RPMI 1640 medium without propolis was 
used as a positive control. Test suspensions were 
placed on a shaker and incubated at 37°C. At 
predetermined time points (0, 1, 2, 3, 4, 6, 8, 12, 
24, 28 and 36 h), serial dilutions were performed 
on SDA for CFUs determination. Following 
incubation at 37°C for 24 h, the number of CFU 
was determined.
Effect of propolis on filamentation form 
transition
To evaluate the effect of propolis against 
Candida species filamentation four C. albicans, 
four C. parapsilosis and four C. tropicalis clinical 
isolates, and their respective references strains 
were tested. The clinical isolates were chosen 
randomly. Candida cells were grown overnight 
in YPD (1% yeast extract; 2% peptone; 2% 
dextrose) medium. And then, 1 × 106 yeasts/ml 
were incubated in RPMI 1640 medium with 
10% fetal bovine serum (FBS), in the presence 
or absence of PE (450 μg/ml of TPC, selected 
in order to use a concordant concentration to all 
species in accordance with its MICs values), at 
37°C for 4 h. Blastospore and filamentous forms 
were counted by observation under a phase 
contrast microscope, according to the criteria 
described by Toenjes et al. (2005) [39]. More than 
100 cells were counted, in duplicate, for each 
strain. Additionally, images of cell morphologies 
were obtained, after staining the microorgan-
isms with calcofluor white (Sigma-Aldrich, St 
Louis, Missouri, EUA). The cells were visualized 
with BX51 Olympus epifluorescence microscope 
coupled with a DP72 digital camera (Olympus 
Portugal SA, Porto, Portugal). All images were 
acquired using the Olympus Cell-B software.
●● Antibiofilm effect of propolis
As known, biofilms are microorganism’s com-
munity described as ten a 100-times more resist-
ance than its counterpart’s planktonic cells [7]. 
Thus, the PE concentrations used in this part of 
the study were based on this concept and on our 
previous findings of antimicrobial susceptibility.
Influence of propolis on biofilm formation
In order to evaluate the effect of PE on Candida 
species’ biofilm formation, PE was added after 
adhesion phase (2 h). For that, Candida cells 
were grown on SDA for 24 h at 37°C, then 
inoculated in SDB and incubated for 18 h at 
37°C under agitation at 120 rpm. After incu-
bation, cells were harvested by centrifugation 
at 3000 × g for 10 min, at 4°C, and washed 
twice with 15 ml of phosphate-buffered saline 
([PBS]; pH 7; 0.1 M). Cell suspensions of 
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1 × 105 yeasts/ml were prepared in RPMI 1640 
medium, 200 μl of suspensions were inoculated 
into 96-well polystyrene plates, and incubated 
at 37°C on a shaker at 120 rpm/min for 2 h, to 
allow attachment of cells to the abiotic surface. 
Nonadhered cells were removed by wash with 
sterile PBS. And then 200 μl of PE (concentra-
tions of 500, 700 and 1400 μg/ml of TPC in 
RPMI 1640 medium) were added to each well. 
The plates were incubated at 37°C for 24 h 
to allow biofilm formation. Negative controls 
(200 μl of only RPMI 1640 medium) were also 
included.
Biofilms were analyzed by CFU determina-
tion. For that, the total medium was removed 
and the biofilms washed once with 200 μl of 
PBS. Then, the biofilms were scraped from the 
respective wells and the suspensions vigorously 
vortexed for approximately 2 min to disaggregate 
cells from the matrix [13]. Serial dilutions were 
made in PBS, plated onto SDA and incubated 
for 24 h at 37°C. The results were presented in 
terms of log of CFUs.
Influence of propolis on preformed biofilms
The effect of PE was evaluated on 24 h pre-
formed biofilms. For that, biofilms were formed 
during 24 h, as described above, the medium 
was aspirated and the nonadherent cells were 
removed by washing the biofilms once with 
200 μl of PBS. Then, 200 μl of PE (500, 700 and 
1400 μg/ml of TPC in RPMI 1640 medium) 
were added to each well. The biofilms were incu-
bated for further 24 h, at 37°C on a shaker at 
120 rpm/min. The effect of PE on Candida bio-
films was assessed through quantification of the 
number of CFU as described above. The results 
were presented in terms of log of CFU.
Effect of propolis on biofilm structure
Candida biofilm’s structure and cell morphology, 
after growth in the presence and absence of PE 
(1400 μg/ml of TPC) was characterized by scan-
ning electron microscopy (SEM). Biofilms were 
prepared as described above, but 24-well micro-
titer plates (orange Scientific, Braine-l’Alleud, 
Belgium) were used. The biofilms were dehy-
drated with increasing concentrations of ethanol 
(using 70% ethanol for 10 min, 95% ethanol for 
10 min and 100% ethanol for 20 min) and then 
air dried for 20 min. Samples were kept in a des-
iccator until analysis. Prior to observation, the 
bottom of the wells was removed and mounted 
on aluminium stubs, sputter coated with gold 
and imaged using an S-360 scanning electron 
microscope (Leo, MA, USA).
●● Cytotoxicity assay
Fibroblasts 3T3 (CCL-163) were grown in 
Dulbecco Modified Eagle Medium (DMEM 
– Gibco) containing 10% of calf bovine serum 
(Gibco) and 1% penicillin streptomicin (Gibco). 
After detachment, a suspension with 105 cells/ml 
was added to a 96-well plate and cells were 
allowed to grow until attaining 80% of conflu-
ence. Prior to the cytotoxicity assays, the wells 
were washed twice with PBS. PE (concentrations 
from 220 to 1400 μg/ml of TPC) was added to 
the cells and incubated for 24 h at 37°C under 
5% CO2. Cells treated with the same concentra-
tion of ethanol were used as control. Afterwards, 
cytotoxicity was assessed using the Promega 
CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay, based on the reduction 
of MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-
carboxymethoxyphenyl]-2-[4-sulfophenyl]-
2H-tetrazolium) in DMEM without phenol 
red. After 4 h, the absorbance of the resulting 
solution was read at 490 nm. The cytotoxicity 
of the compound is presented as the average of 
three independent experiments with three repli-
cates [40]. The percentage of cell viability (%CV) 
was calculated by the following equation: %CV 
= (Abs sample/ Abs blank) × 100, where blank is 
the medium with cells and MTS.
●● Statistical analysis
Data are expressed as the mean ± standard 
deviation (SD) of at least three independent 
experiments. Results were compared using 
two-way ANOVA followed by Bonferroni mul-
tiple comparisons, using GraphPad Prism ver-
sion 6 (GraphPad Software, CA, USA). The 
significance level was set at p < 0.05.
Results
●● Preparation & characterization of the 
propolis extract
The green propolis sample used in this study 
was collected from hives located in the North of 
Paraná state (Brazil). The apiary is surrounded 
by native forest with a predominance of Baccaris 
drancunculifolia and eucalyptus reserve. Green 
Brazilian propolis of this region is classified as 
‘type BRP’. In previous studies, the ethanolic 
extracts prepared containing this type of prop-
olis were standardized and already chemically 
characterized [18,41].
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The physicochemical evaluation of PE showed 
that pH was 5.12 ± 0.05 and relative density was 
0.8722 ± 0.0009 g/ml-1. The DR value of the PE 
was determined as 19.33% ± 0.01 (w/w) and the 
TPC value obtained was 1.42% ± 0.07 (w/w). 
These values are in accordance to the literature, 
showing the good physicochemical characteris-
tics of it, and indicating, then, that PE can be 
used in the present study [18,36,41].
●● Effect of propolis on Candida planktonic 
cells 
MICs & MFCs
The results of PE’s MICs 50% (i.e., the con-
centration that was able to inhibit 50% of the 
isolates tested) and 90% (i.e., the concentra-
tion that was able to inhibit 90% of the isolates 
tested) for the different pathogenic yeasts are 
shown in Table 1. PE showed similar and potent 
inhibitory activity against all clinical isolates of 
Candida species with MICs values ranging from 
220 to 880 μg/ml of TPC. In all cases, the MIC 
value was equivalent to its correspondent MFC 
value.
Based in these results, PE concentrations among 
450–1400 μg/ml of TPC were selected to be 
used in the following experiments.
Moreover, the percentage of fibroblasts viabil-
ity, after direct contact with the PE (in these 
concentrations) was determined in order to allow 
cytotoxicity evaluation. Results shown that cyto-
toxicity was below 35% (15–35%), for all the 
PE’s concentrations tested (data not shown).
Time-kill curves determination
The killing activity of PE, plotted from 
log
10
 CFU/ml versus time (36 h), is represented 
in Figure 1. Two distinct effects were observed on 
the growth of the Candida species. At 450 μg/ml 
of TPC, for all species tested, slight inhibi-
tory effect was observed until 12 h, however, 
after this time the resultant curves were nearly 
identical to those for the control. At concen-
tration 900 μg/ml of TPC, a substantial time-
dependent reduction in the number of viable 
cells was observed compared with the control 
group. Additionally, results revealed that the 
PE effect was more pronounced in C. albicans 
and C. parapsilosis species, with a decreased of 
≥99.9% (4 and 3 log) at 36 h, comparatively 
to control group (without PE). In fact even at 
36 h the reduction observed by C. tropicalis did 
not exceed approximately 90% (1.5 log) of the 
reduction. This species had also higher MIC 
to PE, when compared with C. albicans and 
C. parapsilosis.
Propolis effect on Candida species filamentous 
forms formation
The effect of propolis on the transition of yeast to 
filamentous forms was evaluated (Figure 2). Four 
clinical isolates of C. albicans, C. tropicalis and 
C. parapsilosis species and the respective refer-
ence strains were analyzed. The results revealed 
that C. parapsilosis was unable to form filamen-
tous forms (data not shown) and that C. albicans 
presented higher number of filamentous forms 
than C. tropicalis. It was also observed that PE 
(at concentration of 450 μg/ml of TPC), after 
4 h of exposition, reduced approximately from 
80 to 5% the formation of filamentous forms on 
all C. albicans and C. tropicalis strains (Figure 2).
●● Propolis antibiofilm activity
The second aim of this work was to evaluate the 
activity of propolis on Candida biofilms forma-
tion (Figure 3) and against Candida preformed 
biofilms (Figure 4). The results revealed that PE 
was able to reduce Candida biofilms, however, 
in a species- and strain-dependent manner. 
Concerning the effect of the PE on biofilm for-
mation the results revealed a significant reduc-
tion in the number of cultivable cells for the 
four clinical isolates of the each species and its 
Table 1. In vitro Candida species antifungal susceptibility to propolis extract and fluconazole.
Candida species  Antifungal agent MIC (μg/ml)
Range MIC 50 MIC 90
C. albicans 
 
PE
FLU
440
≤0.125–0.25 (S)
440
0.125
440
0.25
C. parapsilosis 
 
PE
FLU
220–880
0.25–4.0 (S)
220
0.5
440
2.0
C. tropicalis
 
PE
FLU
440–880
0.25–16 (S–DDS)
880
0.5
880
8.0
MIC 50 and MIC 90: MIC that could inhibit 50 and 90% of the growth of the isolates, respectively.
DDS: Dose-dependent susceptible; FLU: Fluconazole; PE: Propolis extract; S: Susceptible.
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Figure 1.  Killing kinetics of propolis extract against Candida species. (A) C. albicans American 
Type Culture Collection (ATCC) 90028; (B) C. parapsilosis ATCC 22019; (C) C. tropicalis ATCC 40042. 
Standardized yeast cells suspensions were exposed to 450 and 900 μg/ml of total phenol contents. 
At determined time intervals, samples were serially diluted and plated for colony counts. Each data 
point represents mean result ± standard deviation (error bars) from three experiments.
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respective reference strains (Figure 3A). No sig-
nificant differences were observed between the 
three PE concentrations tested. Candida albi-
cans strains presented the highest biofilm reduc-
tion (∼3.5 log), followed by C. parapsilosis and 
C. tropicalis, with a reduction approximately 2.8 
and 2 log, respectively, for all PE concentrations 
tested (Figure 3A).
The propolis effect against preformed 
Candida biofilms (Figure 4A) was lower com-
paratively to the effect on biofilm formation. In 
fact, at the biofilm maturation stage, no biofilm 
reduction was observed for 500 μg/ml of TPC 
for all Candida strains under study. Moreover, 
with PE concentrations ≥700 μg/ml of TPC 
the preformed biofilm reduction was similar to 
those observed for the biofilm formation, when 
compared with the control group. Concerning 
C. tropicalis, PE at 500 and 700 μg/ml of TPC 
was able to reduce approximately 1.5 and 2.4 log, 
respectively. This reduction was higher than 
the observed in the biofilm formation studies 
(Figure 3A), even to for PE concentrations of 
the 1400 μg/ml of TPC where it was observed 
a reduction of approximately 3.5 log in the 
number of CFUs.
●● Effect of propolis on biofilm structure
SEM analysis was performed to examine the 
effect of the PE on Candida species biofilm for-
mation (Figure 3B) and against preformed bio-
films (Figure 4B). For that, biofilms of one clinical 
isolate and its respective reference strain were 
treated with PE at 1400 μg/ml of TPC and 
compared with untreated biofilms.
Examination of untreated biofilms showed 
the presence of different cellular morphologies 
in the Candida biofilms. Candida albicans and 
C. parapsilosis biofilms exhibited a blastoconidia 
aggregate layer with irregular clusters, while 
C. tropicalis biofilms developed a more compact 
and continuous structure with yeast cells more 
interlinked (Figures 3B & Figure 4B: Controls). 
Interestingly, it was observed that Candida spe-
cies’ biofilms when treated with PE (1400 μg/ml 
of TPC) presented a significant reduction on the 
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Figure 2.  Inhibition of C. albicans and C. tropicalis filamentation by propolis extract in fetal bovine serum RPMI 1640 medium at 
37°C for 4 h. (A) Percentage of the filamentous forms observed after exposing Candida planktonic cells to propolis (treated). (B) The 
images are representative of C. albicans and C. tropicalis cells obtained using a fluorescent microscope stained with calcofluor white. 
Propolis extract was added at a concentration of 450 μg/ml. The asterisks represent propolis residues. 
ATCC: American Type Culture Collection.
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number of cells and a consistent biofilm disrup-
tion (Figures 3B & Figure 4B: Treated). In addi-
tion, yeasts cells on biofilms treated with PE 
underwent morphological alterations and loss 
of integrity on their cell wall. Moreover, in the 
presence of PE, C. albicans biofilms presented a 
reduction in the number of filamentous forms.
Discussion
The incidence of candidiasis in the last two dec-
ades had a significant increment and C. albicans 
is still the most prevalent species, however, the 
frequency of the NCAC species has also been 
increasing [42–44]. This fact can be due to the 
lower sensibility of the yeasts to the antifungal 
agents most commonly used in clinical prac-
tice [45]. Moreover, the expression of the viru-
lence factors, such as morphological transition 
and biofilm formation has been associated to 
difficulties on their treatment [2,46]. The increas-
ing incidence of drug-resistant pathogens, the 
limited number of therapeutic options and the 
toxicity of traditional compounds have drawn 
attention towards the antimicrobial activity of 
natural products encouraging the development 
of alternative treatments [47].
Propolis has been demonstrated important 
antimicrobial activity and this bioactivity has 
been investigated in the last years [24,48]. The 
antimicrobial activity of propolis is complex and 
has been attributed to the synergistic activity 
between its various potent biological ingredients, 
mainly phenolic and flavonoid compounds [49]. 
The flavonoids constitute a very important class 
of polyphenols, widely present in propolis [50]. 
The great part of propolis biological activity is 
attributed to polyphenols [51]. Green Brazilian 
propolis type BRP is rich source of phenolic sub-
stances; most of them are prenylated phenylpro-
panoids, and cinnamic acids, chiefly compounds 
bearing prenyl groups [18,36,41]. Therefore, the 
physicochemical analysis is fundamental for the 
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Figure 3.  Logarithm of number of Candida cells biofilms (A) and scanning electron microscopy images (B) of propolis extract 
effect during biofilm formation by Candida species. Candida cells, were allowed to adhere for 2 h, then propolis was added and 
incubated further for 24 h at 37°C. Error bars represented in graphics indicate the standard deviation. In the images (a1 & a2) represent 
isolate clinical C. albicans (a3 & a4) ATCC C. albicans 90028 (b1 & b2) isolate clinical C. parapsilosis (b3 & b4) ATCC C. parapsilosis 22019 
(c1 & c2) isolate clinical C. tropicalis (c3 & c4) ATCC C. tropicalis 40042. 
*, ** and **** correspond to p < 0.05, p < 0.01 and p < 0.0001, respectively. 
Controls: biofilms grown in RPMI medium in the absence of propolis extract; Treated: biofilms grown in RPMI medium in the presence of 
1400 μg/ml of total phenol content. The bar in the images corresponds to 20 μm. Magnification × 1000. 
ATCC: American Type Culture Collection.
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evaluation of PE quality. The results showed the 
good characteristics of PE and the spectropho-
tometric determination of TPC was useful to 
characterize the amount of polyphenols. The 
value obtained was 1.42% ± 0.07 (w/w) of TPC, 
and this amount is in accordance with other 
researches [36,41].
Despite some work developed about the 
effect of propolis against virulence factors of 
C. albicans [24,30–31] scarce are the studies involv-
ing NCAC species. Thus, the main goal of this 
study was to investigate the effect of propolis 
on the three most important Candida species, 
C. albicans, C. tropicalis and C. parapsilosis. 
It was a goal to evaluate the effect on both 
planktonic cells and biofilms.
Firstly, the planktonic susceptibility of 
C. albicans, C. tropicalis and C. parapsilosis 
strains to PE was determined (Table 1). Our 
data demonstrated that, all Candida species 
were susceptible to PE with a MIC range of 
220 to 880 μg/ml of TPC. Moreover, these 
work showed that PE was effective even against 
strains with sensitivity dose dependence to 
fluconazole (MIC 16 μg/ml), namely in the 
case of C. tropicalis. Therefore these results 
are in agreement with Dalben-Dota et al. 
(2010) [36] that showed Candida species’ sen-
sitivity to PE. These authors observed that the 
MIC of PE ranged from 6.14 to 3145.50 mg/ml 
of flavonoids content (which are included in 
polyphenol content), evidencing an efficacy of 
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Figure 4.  Logarithm of number of Candida cells biofilms (A) and scanning electron microscopy images (B) of propolis extract 
effect on preformed Candida species biofilms. Candida cells, were allowed to form biofilm for 24 h, then propolis was added and 
incubated further for 24 h at 37°C. Error bars represented in graphics indicate the standard deviation. In the images (a1 & a2) represent 
isolate clinical C. albicans (a3 & a4) ATCC C. albicans 90028 (b1 & b2) isolate clinical C. parapsilosis (b3 & b4) ATCC C. parapsilosis 22019 
(c1 & c2) isolate clinical C. tropicalis (c3 & c4) ATCC C. tropicalis 40042. 
*, ** and **** correspond to p < 0.05, p < 0.01 and p < 0.0001, respectively. 
Controls: biofilms grown in RPMI medium in the absence of propolis extract; Treated: biofilms grown in RPMI medium in the presence of 
1400 μg/ml of total phenol content. The bar in the images corresponds to 20 μm. Magnification × 1000. 
ATCC: American Type Culture Collection.
****
****
****
****
*
****
****
****
****
0
1
2
4
5
7
8
C. albicans
N
u
m
b
er
 o
f 
vi
ab
le
 
ye
as
t 
(l
o
g
 C
F
U
 m
l-1
)
Ca555 ATCC
90028
6
3
Ca620Ca157Ca127
****
****
***
****
****
****
****
****
****
****
0
1
2
4
5
7
8
C. parapsilosis
N
u
m
b
er
 o
f 
vi
ab
le
 
ye
as
t 
(l
o
g
 C
F
U
 m
l-1
)
Cp574 ATCC
22019
6
3
Cp412Cp397Cp303
********
**
****
**
****
***
**
***
****
0
1
2
4
5
7
8
C. tropicalis
N
u
m
b
er
 o
f 
vi
ab
le
 
ye
as
t 
(l
o
g
 C
F
U
 m
l-1
)
Ct630 ATCC
40042
6
3
Ct624Ct606Ct497
*** ***
* **
Control
500 µg/ml
700 µg/ml
1400 µg/ml
a1
a2 a4
a3 b1
b2 b4
b3 c1
c2 c4
c3
Tr
ea
te
d
C
o
n
tr
o
ls
A
B
Propolis: a potential natural product to fight Candida species infections RESEaRch aRticlE
future science group www.futuremedicine.com
this extract. A time-kill assay was performed to 
determine the kinetic effect of PE on C. albi-
cans, C. parapsilosis and C. tropicalis growth 
(Figure 1) . Results revealed approximately 
90% of reduction on its growth for all spe-
cies, with an effective reduction on Candida 
cells cultivability. In fact PE was able to reduce 
around three logs (99.9%) of C. albicans and 
C. parapsilosis and an approximately 1.5 log 
of C. tropicalis. These results are in accord-
ance with the susceptibility results where, 
C. tropicalis was the species with the highest 
MIC value.
As previous works only showed an effec-
tive activity of PE against planktonic Candida 
species cells [36,52] this work intends to extend 
this knowledge, by evaluating the PE’s effect 
on Candida species virulence traits, such as 
yeast-filamentous transition and biofilm for-
mation ability. It is known that the formation 
of hyphae helps C. albicans to penetrate the 
host tissues with subsequent invasiveness that 
leads to the establishment of infection [53]. 
Thus, the ability of PE to inhibit the for-
mation of filamentous forms was evaluated 
and the results revealed that PE was able to 
block 90% of the yeast- filamentous forms in 
C. albicans and C. tropicalis (Figure 2). This 
inhibition of yeast-filamentous’ forms transi-
tion by PE, presents a very attractive option to 
control Candida infections. It was previously 
reported that the morphological switch from 
yeast to hyphae cells is important in many pro-
cesses, such as biofilm formation [54]. Thus, 
the high capacity of PE to efficiently inhibit 
yeast-hyphae transition may be associated 
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with its ability to prevent biofilm formation. 
Furthermore, this product has received the 
attention of clinicians and researchers due to 
its diverse pharmacological activities and low 
toxicity [20,55].
Biofilm formation by microorganisms is a 
mechanism that allows them to become persis-
tent colonizers, to resist clearance by the host 
immune system and antibiotic’s effect [56]. 
Interestingly, it was observed that PE was 
able to inhibit biofilm formation (Figure 3) 
and to destroy mature biofilms (Figure 4) of 
C. albicans, C. parapsilosis and C. tropicalis 
strains. It is important to highlight that PE 
at 450 and 700 μg/ml of TPC was able to 
inhibit approximately 90% of biofilm forma-
tion (Figure 3A) and 1400 μg/ml of TPC was 
able to reduce preformed biofilms in 99.9% 
(Figure 4A) . Previous studies have shown 
that different concentrations of propolis 
(0.25–1.25%) were able to reduce 40–45% of 
the in vitro C. albicans biofilm formation [57]. 
Moreover, Capoci et al. (2014) also revealed a 
small reduction on C. albicans biofilm forma-
tion (<0.5 log) at concentration of PE lower 
than MIC [24]. However, the promising results 
obtained for C. tropicalis and C. parapsilosis 
were never stated before. The SEM images 
corroborate the biofilm disruption (Figures 3B 
& Figure 4B), also demonstrated by cultivable 
cells determination (Figures 3A & Figure 4A), 
reinforcing the PE’s capability to inhibit 
filamentation (Figure 2).
EXEcUtiVE SUMMaRY
 ●  Propolis presents potential antifungal activity.
 ●  Propolis is a stronger inhibitor of filamentous forms formation.
 ●  Propolis is able to reduce and destroy Candida species biofilms.
 ●  Propolis is a promising alternative to antifungal traditional therapy.
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